Program Director: Joyce O’Shaughnessy, MD Co-Director, Breast Cancer Research Baylor Charles A. Sammons Cancer Center Texas Oncology/The US Oncology Network Dallas, TX
Featured Faculty: Hope Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education UCSF Medical Center San Francisco, CA Mark Robson, MD Clinic Director of the Clinical Genetics Service Memorial Sloan-Kettering Cancer Center New York, NY Joseph Sparano, MD Professor of Medicine and Women’s Health Associate Chairman, Clinical Research Albert Einstein College of Medicine Bronx, NY Steven Come, MD Associate Professor, Department of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Boston, MA Chau Dang, MD Memorial Sloan-Kettering Cancer Center New York, NY Andrew Seidman, MD Memorial Sloan-Kettering Cancer Center New York, NY David Euhus, MD, FACS Professor of Surgery, Marilyn R. Corrigan Distinguished Chair in Breast Cancer Surgery Division of Surgical Oncology The University of Texas Southwestern Medical Center at Dallas Dallas, TX John Ng, MD Assistant Professor Weill Cornell Medical College New York Presbyterian Hospital New York, NY Eleftherios (Terry) Mamounas, MD, MPH, FACS Medical Director of the Comprehensive Breast Cancer Program MD Anderson Cancer Center, Orlando Orlando, FL
Alice Y. Ho, MD, MBA Memorial Sloan-Kettering Cancer Center New York, NY
NOTE: This activity was presented live on October 19, 2013. If you received CME credit for attending the live activity, you are not eligible to receive credit for this online release. This program features a diverse panel of internationally recognized breast cancer experts presenting on the increasing number of breast cancer subtypes that challenge oncologists. A significant emphasis on case discussions and new data supporting treatment options provide practical applicability of the data and evolving clinical trial findings. Other topics pertaining to predictive biomarkers, staging, risk assessment, toxicity management, and survivorship are addressed. Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.
Upon completion of this educational activity, the participant should be able to:
Discuss the use of molecular assays and biomarkers to assess recurrence risk and predict benefit from therapy for individual patients.
Analyze strategies for managing patients with metastatic breast cancer through multiple lines of therapy, including assessment of efficacy and safety profiles of available regimens as well as patient comorbidities and prior treatments, in order to tailor and personalize therapy.
Assess the impact of breast cancer subtype on the efficacy of chemotherapy, endocrine therapy, or targeted therapy in order to optimize treatment selection for individual patients.
Evaluate data from recent adjuvant and neoadjuvant clinical trials in order to optimize and individualize treatment with cytotoxic, endocrine, or targeted agents for patients with early-stage breast cancer.
Utilize recent data on surgical and radiation therapy in defined patient subgroups in order to select the appropriate local control strategy for individual patients.
Incorporate current expert guideline recommendations for the treatment of early-stage and metastatic breast cancer.
In compliance with ACCME guidelines, Imedex is providing a list of the individuals in a position to control/influence the content of this CME activity and their relevant financial relationships with commercial interests (or absence thereof). Imedex has used a multi-step process to resolve all COI.
Dr. O’Shaughnessy discloses a financial relationship with Genentech (advisory board), Amo Therapeutics, Eisai, Genentech, GlaxoSmithKline; Johnson & Johnson, Sanofi-aventis, Novartis, Pfizer, Celgene, Concept Therapeutics, MED Fusion LLC (paid consultant).
Dr. Rugo discloses a financial relationship with Merck, Novartis and Pfizer (grants to UCSF).
Dr. Robson discloses a financial relationship with AstraZeneca, AbbVie, Biomarin, Bayer, and Tesaro.
Dr. Sparano does not have any relevant financial relationships with any commercial interests.
Dr. Come does not have any relevant financial relationships with any commercial interests.
Dr. Dang discloses a financial relationship with Roche/Genentech, and GlaxoSmithKline (research funding).
Dr. Seidman discloses a financial relationship with Genentech (speaker).
Dr. Euhus does not have any relevant financial relationships with any commercial interests.
Dr. Ng does not have any relevant financial relationships with any commercial interests.
Dr. Mamounas discloses a financial relationship with Genomic Health (speaker) and GE Healthcare, Eisai and Celgene (consultant).
Dr. Ho does not have any relevant financial relationships with any commercial interests.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Imedex and MCM Education. Imedex is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex designates this enduring material for a maximum of 7.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credits TM from organizations accredited by the ACCME. Commercial Support Statements
This activity is supported by educational grants from Genentech, Novartis, and Eisai Inc.
This CME activity may discuss the investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for all products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Imedex, MCM Education, or any of the companies that provided commercial support for this CME activity.